{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:31Z","timestamp":1790898931301,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00825-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:08:14Z","timestamp":1788192494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-9679","authenticated-orcid":false,"given":"Jos\u00e9 Pablo","family":"Miramontes Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"39","key":"825_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"1","key":"825_CR2","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48\u201360. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"825_CR3","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, et al. A focused update to the 2019 National Lipid Association scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"825_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Emerging risk factors collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u201323. https:\/\/doi.org\/10.1001\/jama.2009.1063.","journal-title":"JAMA"},{"issue":"1","key":"825_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315291.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"825_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008;117(2):176\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.715698.","journal-title":"Circulation"},{"issue":"22","key":"825_CR7","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139. https:\/\/doi.org\/10.1001\/jama.2009.801.","journal-title":"JAMA"},{"issue":"22","key":"825_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","volume":"391","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med. 2024;391(22):2087\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2405182.","journal-title":"N Engl J Med"},{"issue":"3","key":"825_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamacardio.2023.5605","volume":"9","author":"AM Small","year":"2024","unstructured":"Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, et al. Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations. JAMA Cardiol. 2024;9(3):233\u201342. https:\/\/doi.org\/10.1001\/jamacardio.2023.5605.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"825_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"825_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/CIRCULATIONAHA.124.069582","volume":"150","author":"JK Grant","year":"2024","unstructured":"Grant JK, Martin SS, Zhang S, Matsushita K, Virani SS, Blumenthal RS, et al. Racial differences in the burden of atherosclerotic cardiovascular disease related to elevated lipoprotein(a) levels: the ARIC study. Circulation. 2024;150(3):250\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069582.","journal-title":"Circulation"},{"issue":"1","key":"825_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","volume":"74","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54\u201366. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.524.","journal-title":"J Am Coll Cardiol"},{"key":"825_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117437","volume":"389","author":"P Welsh","year":"2024","unstructured":"Welsh P, Al Zabiby A, Byrne H, Benbow HR, Itani T, Farries G, et al. Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: a cohort study from the UK Biobank. Atherosclerosis. 2024;389:117437. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117437.","journal-title":"Atherosclerosis"},{"key":"825_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120420","volume":"408","author":"S Xie","year":"2025","unstructured":"Xie S, Galimberti F, Olmastroni E, Carugo S, Catapano AL, Casula M. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis. 2025;408:120420. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120420.","journal-title":"Atherosclerosis"},{"issue":"10155","key":"825_CR15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","volume":"392","author":"P Willeit","year":"2018","unstructured":"Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual-patient-data meta-analysis of statin outcome trials. Lancet. 2018;392(10155):1311\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(18)31652-0.","journal-title":"Lancet"},{"issue":"24","key":"825_CR16","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310.","journal-title":"Eur Heart J"},{"issue":"5","key":"825_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","volume":"29","author":"LM de Boer","year":"2022","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(5):779\u201392. https:\/\/doi.org\/10.1093\/eurjpc\/zwab171.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"825_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36204-7","volume":"8","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mendia LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8(1):17887. https:\/\/doi.org\/10.1038\/s41598-018-36204-7.","journal-title":"Sci Rep"},{"issue":"24","key":"825_CR19","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, AIM-HIGH Investigators, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1107579.","journal-title":"N Engl J Med"},{"issue":"3","key":"825_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","unstructured":"HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312. https:\/\/doi.org\/10.1056\/NEJMoa1300955.","journal-title":"N Engl J Med"},{"issue":"12","key":"825_CR21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483\u201392. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184.","journal-title":"Circulation"},{"issue":"2","key":"825_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"825_CR23","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","volume":"44","author":"E Gianos","year":"2024","unstructured":"Gianos E, Koschinsky ML, Mani V, Weintraub HS, Tsimikas S, Moriarty PM, et al. Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2024;44(12):e304\u201321. https:\/\/doi.org\/10.1161\/ATV.0000000000000177.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"825_CR24","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","volume":"36","author":"E Roeseler","year":"2016","unstructured":"Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization. Arterioscler Thromb Vasc Biol. 2016;36(9):2019\u201327. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307983.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"825_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"key":"825_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","volume":"287","author":"L Cho","year":"2025","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, et al. Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J. 2025;287:1\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2025.03.019.","journal-title":"Am Heart J"},{"issue":"20","key":"825_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"issue":"9","key":"825_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","volume":"84","author":"ML O'Donoghue","year":"2024","unstructured":"O\u2019Donoghue ML, Rosenson RS, L\u00f3pez JAG, Lepor NE, Baum SJ, Stout E, et al. The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results. J Am Coll Cardiol. 2024;84(9):790\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.058.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"825_CR29","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamacardio.2024.5433","volume":"10","author":"RS Rosenson","year":"2025","unstructured":"Rosenson RS, L\u00f3pez JAG, Gaudet D, Baum SJ, Stout E, Lepor NE, et al. Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial. JAMA Cardiol. 2025;10(5):482\u20136. https:\/\/doi.org\/10.1001\/jamacardio.2024.5433.","journal-title":"JAMA Cardiol"},{"issue":"18","key":"825_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA. 2024;331(18):1534\u201343. https:\/\/doi.org\/10.1001\/jama.2024.4504.","journal-title":"JAMA"},{"issue":"23","key":"825_CR31","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024;332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/jama.2024.21957.","journal-title":"JAMA"},{"issue":"21","key":"825_CR32","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330(21):2075\u201383. https:\/\/doi.org\/10.1001\/jama.2023.21835.","journal-title":"JAMA"},{"issue":"17","key":"825_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran\u2014a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med. 2025;392(17):1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2415818.","journal-title":"N Engl J Med"},{"issue":"11","key":"825_CR34","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","volume":"330","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330(11):1042\u201353. https:\/\/doi.org\/10.1001\/jama.2023.16503.","journal-title":"JAMA"},{"issue":"3","key":"825_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2025;333(3):222\u201331. https:\/\/doi.org\/10.1001\/jama.2024.24017.","journal-title":"JAMA"},{"issue":"1","key":"825_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/ijms24010170","volume":"24","author":"A Pirillo","year":"2022","unstructured":"Pirillo A, Norata GD, Catapano AL. Lipoprotein(a): pathophysiology, measurement, and treatment. Int J Mol Sci. 2022;24(1):170. https:\/\/doi.org\/10.3390\/ijms24010170.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"825_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/0115701611267835231210054909","volume":"22","author":"D Mukherjee","year":"2024","unstructured":"Mukherjee D, Nissen SE. Lipoprotein(a) as a biomarker for cardiovascular diseases and potential new therapies to mitigate risk. Curr Vasc Pharmacol. 2024;22(3):171\u20139. https:\/\/doi.org\/10.2174\/0115701611267835231210054909.","journal-title":"Curr Vasc Pharmacol"},{"issue":"8","key":"825_CR38","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57(8):1339\u201359. https:\/\/doi.org\/10.1194\/jlr.R067314.","journal-title":"J Lipid Res"},{"key":"825_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","volume":"355","author":"SB Simony","year":"2022","unstructured":"Simony SB, Mortensen MB, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study. Atherosclerosis. 2022;355:76\u201382. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.1023.","journal-title":"Atherosclerosis"},{"key":"825_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","volume":"349","author":"B Enkhmaa","year":"2022","unstructured":"Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53\u201362. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.006.","journal-title":"Atherosclerosis"},{"issue":"4","key":"825_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","volume":"59","author":"JC Hopewell","year":"2018","unstructured":"Hopewell JC, Haynes R, Baigent C. The role of lipoprotein(a) in chronic kidney disease. J Lipid Res. 2018;59(4):577\u201385. https:\/\/doi.org\/10.1194\/jlr.R083626.","journal-title":"J Lipid Res"},{"issue":"1","key":"825_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.12981","volume":"287","author":"A Vuorio","year":"2020","unstructured":"Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287(1):2\u201318. https:\/\/doi.org\/10.1111\/joim.12981.","journal-title":"J Intern Med"},{"key":"825_CR43","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40292-026-00781-w","volume":"33","author":"C Tognola","year":"2026","unstructured":"Tognola C, Bernasconi DP, Rebora P, et al. Lipoprotein(a) does not correlate with hypertensive mediated organ damage and subsequent cardiovascular events in a primary prevention cohort. High Blood Press Cardiovasc Prev. 2026;33:425\u201337. https:\/\/doi.org\/10.1007\/s40292-026-00781-w.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"825_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40292-023-00607-z","volume":"30","author":"A Maloberti","year":"2023","unstructured":"Maloberti A, Intravaia RCM, Mancusi C, et al. Secondary prevention and extreme cardiovascular risk evaluation (SEVERE-1), focus on prevalence and associated risk factors: the study protocol. High Blood Press Cardiovasc Prev. 2023;30:573\u201383. https:\/\/doi.org\/10.1007\/s40292-023-00607-z.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"825_CR45","doi-asserted-by":"publisher","DOI":"10.2174\/011871529X390148250908045359","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Sharma K, Mukherjee D. Lepodisiran: effects on lipoprotein(a) and cardiovascular outcomes in adults with elevated Lp(a). Cardiovasc Hematol Disord Drug Targets. 2025. https:\/\/doi.org\/10.2174\/011871529X390148250908045359. (Epub ahead of print).","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"825_CR46","doi-asserted-by":"publisher","DOI":"10.2174\/011871529X399029250923100015","author":"K Sharma","year":"2025","unstructured":"Sharma K, Kattamuri L, Mukherjee D. Lipoprotein(a) lowering with pelacarsen (TQJ230). Cardiovasc Hematol Disord Drug Targets. 2025. https:\/\/doi.org\/10.2174\/011871529X399029250923100015. (Epub ahead of print).","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"825_CR47","doi-asserted-by":"publisher","DOI":"10.2174\/011871529X520042260627210331","author":"D Mukherjee","year":"2026","unstructured":"Mukherjee D, Lange R. Effective lowering of lipoprotein(a)\u2014a new frontier in cardiovascular risk reduction. Cardiovasc Hematol Disord Drug Targets. 2026. https:\/\/doi.org\/10.2174\/011871529X520042260627210331. (Epub ahead of print).","journal-title":"Cardiovasc Hematol Disord Drug Targets"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00825-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00825-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:23:06Z","timestamp":1790896986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00825-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":47,"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00825-5","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the author's family name.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jos\u00e9 Pablo Miramontes Gonz\u00e1lez declares no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing not applicable to this article as no datasets were generated for it.","order":2,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}